hotspot -WSS

hotspot

author：focus 2025-09-28 00:50:04 - browse：9416

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： SEC charges former device maker CEO with $41 million fraud

WSS

How to keep neuroscience’s past racism from being its future

Drinking less cuts risk of oral cavity, esophageal cancer: Report

CRISPR gene editing developments we’re watching in 2024

Why health care costs have stayed mostly flat since 2010

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Carvykti CAR

leisure time

hotspot

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

A revolution in caring for preterm infants

Moonlake's readout produced a cash windfall. Risks remain

Violet CEO on training clinicians to promote more inclusive care

How to save PrEP access — and even expand it

Virtual care provider acquires bankrupt Pear's prescription apps

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Cancer cells are shown to suck energy source from immune cells

At least 13 dead in Texas as scorching temps continue

Virtual care provider acquires bankrupt Pear's prescription apps

focus

In Spain, a hospital brews its own CAR

Can sheer will power keep patients alive in their dying hours?

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Bristol Myers buys into radiopharmaceuticals with RayzeBio

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Readout LOUD podcast: Merger Mondays, Ozempic panic

hotspot

explore

knowledge

hotspot